Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario

被引：10

作者：

Bertaglia, Valentina ^{[1
]}

Morelli, Anna Maria ^{[2
]}

Solinas, Cinzia ^{[3
]}

Aiello, Marco Maria ^{[4
]}

Manunta, Silvia ^{[5
]}

Denaro, Nerina ^{[6
]}

Tampellini, Marco ^{[2
]}

Scartozzi, Mario ^{[3
]}

Novello, Silvia ^{[1
]}

机构：

[1] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, I-10043 Orbassano, Torino, Italy

[2] ASL TO3 Osped Infermi, Med Oncol, I-10098 Rivoli, Torino, Italy

[3] Policlin Monserrato, Med Oncol, AOU Cagliari, I-09042 Monserrato, Cagliari, Italy

[4] AOU Policlin Vittorio Emanuele Catania, Med Oncol, I-95100 Catania, Italy

[5] Osped Civile Alghero, Med Oncol, I-07041 Alghero, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Oncol Dept, I-20122 Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 184卷

关键词：

Non small cell lung cancer; Risk of infections; Immunotherapy; Targeted therapy; IMMUNE CHECKPOINT INHIBITORS; DABRAFENIB PLUS TRAMETINIB; POSITIVE SOLID TUMORS; CHRONIC HEPATITIS-B; OPEN-LABEL; 1ST-LINE TREATMENT; INTEGRATED ANALYSIS; SINGLE-ARM; PHASE-III; MULTICENTER;

D O I：

10.1016/j.critrevonc.2023.103954

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with a diagnosis of lung cancer are often vulnerable to infection, and the risk is increased by tumorassociated immunosuppression and the effects of the treatments. Historically, links between the risk of infection and cytotoxic chemotherapy due to neutropenia and respiratory syndromes are well established. The advent of tyrosine kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)/programmed cell death- ligand 1 (PD-L1) axis and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have changed the treatment paradigm for lung cancer patients. Our understanding of the risk of infections while administrating these drugs is evolving, as are the biological mechanisms that are responsible. In this overview, we focus on the risk of infection with the use of targeted therapies and ICIs, summarizing current evidence from preclinical and clinical studies and discussing their clinical implications.

引用

页数：17

共 110 条

[11] A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer [J].

Braicu, Cornelia ;

Buse, Mihail ;

Busuioc, Constantin ;

Drula, Rares ;

Gulei, Diana ;

Raduly, Lajos ;

Rusu, Alexandru ;

Irimie, Alexandru ;

Atanasov, Atanas G. ;

Slaby, Ondrej ;

Ionescu, Calin ;

Berindan-Neagoe, Ioana .

CANCERS, 2019, 11 (10)

[12] Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population [J].

Brzezianska, Ewa ;

Karbownik, Malgorzata ;

Migdalska-Sek, Monika ;

Pastuszak-Lewandoska, Dorota ;

Wloch, Jan ;

Lewinski, Andrzej .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2006, 599 (1-2) :26-35

[13] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[14] RET Fusion Genes in Non-Small-Cell Lung Cancer [J].

Chao, Bo H. ;

Briesewitz, Roger ;

Villalona-Calero, Miguel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) :4439-4441

[15] Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis [J].

Chen, Yuzhong ;

Wen, Shaodi ;

Wu, Yuan ;

Shi, Lin ;

Xu, Xiaoyue ;

Shen, Bo .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163

[16] NTRK fusion-positive cancers and TRK inhibitor therapy [J].

Cocco, Emiliano ;

Scaltriti, Maurizio ;

Drilon, Alexander .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :731-747

[17] Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors [J].

Davare, Monika A. ;

Vellore, Nadeem A. ;

Wagner, Jacob P. ;

Eide, Christopher A. ;

Goodman, James R. ;

Drilon, Alexander ;

Deininger, Michael W. ;

O'Hare, Thomas ;

Druker, Brian J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (39) :E5381-E5390

[18] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[19] Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations? [J].

De Silva, Pushpamali ;

Aiello, Marco ;

Gu-Trantien, Chunyan ;

Migliori, Edoardo ;

Willard-Gallo, Karen ;

Solinas, Cinzia .

INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (01) :31-41

[20] Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials [J].

Doebele, Robert C. ;

Drilon, Alexander ;

Paz-Ares, Luis ;

Siena, Salvatore ;

Shaw, Alice T. ;

Farago, Anna F. ;

Blakely, Collin M. ;

Seto, Takashi ;

Cho, Byung Chul ;

Tosi, Diego ;

Besse, Benjamin ;

Chawla, Sant P. ;

Bazhenova, Lyudmila ;

Krauss, John C. ;

Chae, Young Kwang ;

Barve, Minal ;

Garrido-Laguna, Ignacio ;

Liu, Stephen V. ;

Conkling, Paul ;

John, Thomas ;

Fakih, Marwan ;

Sigal, Darren ;

Loong, Herbert H. ;

Buchschacher, Gary L., Jr. ;

Garrido, Pilar ;

Nieva, Jorge ;

Steuer, Conor ;

Overbeck, Tobias R. ;

Bowles, Daniel W. ;

Fox, Elizabeth ;

Riehl, Todd ;

Chow-Maneval, Edna ;

Simmons, Brian ;

Cui, Na ;

Johnson, Ann ;

Eng, Susan ;

Wilson, Timothy R. ;

Demetri, George D. .

LANCET ONCOLOGY, 2020, 21 (02) :271-282

← 1 2 3 4 5 6 7 8 9 10 →